50.78
3.11%
-1.63
Praxis Precision Medicines Inc stock is currently priced at $50.78, with a 24-hour trading volume of 270.89K.
It has seen a -3.11% decreased in the last 24 hours and a -7.91% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $52.21 pivot point. If it approaches the $50.42 support level, significant changes may occur.
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Praxis Precision Medicines Inc (PRAX) Net Income 2024
PRAX net income (TTM) was -$123.28 million for the quarter ending December 31, 2023, a +42.40% increase year-over-year.
Praxis Precision Medicines Inc (PRAX) Cash Flow 2024
PRAX recorded a free cash flow (TTM) of -$111.14 million for the quarter ending December 31, 2023, a +40.08% increase year-over-year.
Praxis Precision Medicines Inc (PRAX) Earnings per Share 2024
PRAX earnings per share (TTM) was -$22.59 for the quarter ending December 31, 2023, a +67.68% growth year-over-year.
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
GlobeNewswire Inc.
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
Zacks Investment Research
Praxis Precision Medicines to Participate in Upcoming April Conferences
GlobeNewswire Inc.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
Zacks Investment Research
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
GlobeNewswire Inc.
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Cap:
|
Volume (24h):